Optimizing care for patients with Fabry disease: Interactive case challenges
Released On
June 7, 2024
Expires On
June 7, 2025
Media Type
Internet
Completion Time
60 minutes
Specialty
Cardiology, Case Management, Genetics, Nephrology, Neurology, Pediatrics, Primary Care
Topic(s)
Cardiovascular Disease, Heart, Heart Disease, Pediatrics
This activity is provided by Ology Medical Education.
This activity is supported in part by an independent education grant from Amicus Therapeutics Inc.
Credit Available
- Physicians — maximum of 1.0 AMA PRA Category 1 Credit™
All other healthcare professionals (HCPs) completing this course will be issued a statement of participation.
Target Audience
This activity is designed to meet the educational needs of cardiologists, nephrologists, neurologists, pediatricians, and primary care physicians.
Program Overview
This activity will provide an interactive, patient-focused learning experience on the multidisciplinary management of patients with Fabry disease, a rare multisystemic lysosomal storage disorder resulting from α-galactosidase A (α-Gal A) deficiency leading to progressive accumulation of globotriaosylceramide (Gb3) in diverse tissues and organs, including the heart and kidneys. During the symposium you will hear patients’ personal experiences and be involved in a lively exchange between leading experts and the audience. The clinical journey from diagnosis to treatment will be analyzed, and best practices for multidisciplinary management will be discussed. Furthermore, the experts will review the latest clinical evidence on novel therapies and provide perspectives on treatment strategies.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Identify early signs of the multisystemic manifestations of Fabry disease and apply guideline-recommended criteria and testing algorithms, including screening of at-risk relatives
- Evaluate available clinical data on Fabry disease-specific disease-modifying therapies to support evidence-based treatment decisions
- Develop and implement comprehensive (multidisciplinary, interdisciplinary, integrated) care plans to manage potential disease complications, using organ-specific biomarkers and quality of life (QoL) measures, for disease monitoring
Faculty
Anjay Rastogi, MD, PhD
UCLA David Geffen School of Medicine, Los Angeles, CA, USA
Anjay Rastogi is Professor of Medicine and Clinical Chief of Nephrology at the David Geffen School of Medicine at University College California (UCLA) in Los Angeles, CA, USA. He is also Director of the Nephro-Genetics Program at UCLA, Director of the Diet and Nutrition Kidney Disease Program at UCLA, and Medical Director of the DaVita Brentwood Dialysis Unit among many other professional roles. Professor Rastogi completed an internal medicine residency and nephrology fellowship at UCLA, where he also completed his graduate training under the mentorship of Nobel Laureate Professor, Louis Ignarro. He is board certified in nephrology and has a doctoral degree (PhD) in pharmacology.Professor Rastogi founded, and is the director of, the UCLA CORE Kidney Health Program; this includes the Circle of CORE, a patient advocacy and support group formed by patients that includes kidney recipients and living kidney donors. He also serves as the director of many other programs, including the Genetics Program at UCLA, all of which provide the best comprehensive and integrated care to patients and their families. Professor Rastogi was awarded the UCLA Exceptional MD of the Year Award in 2014 for his demonstration of the UCLA values of compassion, respect, excellence, discovery, integrity, and teamwork. He has also recently received the 2023 Younes Nazarian Medical Humanitarian Prize; the purpose of this award is to recognize UCLA Health visionary practitioners or senior level healthcare providers whose clinical care, medical research, community programs, or technological innovations are advancing humanity.
Dawn A. Laney, MS, CGC, CCRC
Emory University School of Medicine, Emory University, Atlanta, GA, USA
Dawn A. Laney is a genetic counselor, associate professor, clinical researcher, and program leader at the Lysosomal Storage Disease Center, and Director of the Emory Genetic Clinical Trials Center in the Department of Human Genetics, both at Emory University in Atlanta, GA, USA. She earned her master’s degree in medical genetics from Sarah Lawrence College in 1999, followed by certification from the American Board of Genetic Counseling in 2002. Ms Laney’s clinical and research interests focus on Fabry disease. Since joining the Emory Division of Medical Genetics in 2002, she has been involved in the follow-up of abnormal metabolic newborn screening for the whole state of Georgia, the development, and management of a genetic infusion center, and ysosomal storage disease clinical care and research. She is a cofounder of ThinkGenetic, Inc., which empowers patients with information about possible genetic causes for their medical issues and provides real-life answers to their questions about the impact of living with a genetic disease. Ms Laney enjoys writing children's books, most of which are about living with Fabry disease.
John L. Jefferies, MD, MBA, MPH, FACC, FAHA, FAAP, FHFSA, FESC, FRCPE
UCLA David Geffen School of Medicine, Los Angeles, CA, USA
John L. Jefferies is an internationally recognized cardiologist specializing in cardiomyopathies, heart failure, genetics, heritable disease, artificial intelligence (AI) and machine learning, and rare diseases. He is a Professor in the School of Public Health at the University of Memphis, TN, USA, and a Research Member of St Jude Children’s Research Hospital in Memphis, Tennessee. He is also the current Governor of the Tennessee Chapter of the American College of Cardiology, the President of the American Heart Association Mid-South region, and the team cardiologist for the Memphis Grizzlies. Dr Jefferies completed his combined pediatric and adult cardiology training at the Baylor College of Medicine in Houston, TX, USA, and at the Texas Children's Hospital and the Texas Heart Institute, also in Houston; he received an MBA from the Wharton Business School of the University of Pennsylvania, Philadelphia, PA, USA, with a dual major in Management and Entrepreneurship and Innovation. He is actively involved in the advancement of innovative technologies including AI in healthcare, novel strategies for healthcare provision connectivity, precision medicine, diagnosis and management of rare diseases, and patient advocacy. His research is funded by sources including the National Institutes of Health (NIH) and multiple industry partners. He is the Lead Editor of two leading textbooks on cardiology and has authored or co-authored over 300 peer-reviewed manuscripts and book chapters.
Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Ology Medical Education. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation
Physician Credit Designation Statement
The Postgraduate Institute for Medicine designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ABIM-MOC
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Royal College of Physicians and Surgeons of Canada
Through an agreement between the Accreditation Council for Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME's "CME in support of MOC" program in section 3 of the Royal College's MOC Program.
Disclosures of Conflicts of Interest
- FACULTY
- Anjay Rastogi
- Grant/research support: Alnylam Pharmaceuticals, AstraZeneca, Bayer, GlaxoSmithKline, Idorsia Pharmaceuticals, Kadmon Corporation LLC, National Institutes of Health (NIH), Novo Nordisk, Omers, Paladio Group
- Consultant/advisory board: Akebia, Amicus, Ardelyx, AstraZeneca, Aurinia, Chiesi Global, Inc., Chinook Therapeutics, Fresenius Medical Care, Vifor Pharma, GlaxoSmithKline
- Speakers bureau/Honoraria for non-CME: Amgen, AstraZeneca, Aurinia, Bayer, Baxter, Fresenius Medical Care, Sanofi, Vifor Pharma, Natera
- Dawn A. Laney
- Grant/Research support: Amicus Therapeutics, Sanofi Genzyme
- Consultant/advisory board: Amicus Therapeutics, Chiesi, Sanofi Genzyme, Takeda
- Non-mutual funds stock ownership/Stock options: ThinkGenetic, Inc.
- John L. Jefferies
- Employee/Owner: Bristol Myers Squibb
- Grant/Research support: Amicus, Chiesi, NIH, Sanofi Genzyme
- Consultant/advisory board: Amicus, Chiesi, Daxor, Medtronic, Nuwellis, Pfizer, Rocket Therapeutics, Sanofi Genzyme
- Speakers bureau/Honoraria for non-CME: Bristol Myers Squibb, Daxor, Nuwellis, NS Pharma, Sanofi Genzyme
Instructions for Participation and Credit
There are no fees for participating and receiving CME credit for this enduring activity. To receive CME credit participants must:
- Read the CME/CE information and faculty disclosures
- Participate in the online activity
- Take the pre-activity test
- Take the post-activity test and complete the evaluation.
Certificates will be emailed to the participant.
Course Viewing Requirements
Hardware/Software Requirements
This certified CME activity is designed using HTML5 web components. As you navigate the video using the supplied controls, the slides will sync to the speaker.
Supported Browsers (Desktop/Mobile)
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above
Disclosure of Unlabeled Use
Optimizing care for patients with Fabry disease: Interactive case challenges requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
Disclaimer
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
Contact Information
For CME questions please contact: [email protected].